SEED Survey - DAY - Diabetes Awareness & You

We value your opinion. Kindly go through few important questions and share your views on it.

Name

Email ID

Phone No

City

State

Pin Code

PAN

The above information is correct to best of knowledge & I do hereby give my consent to use the information of this survey for research work in future.

1. In routine clinical practice, how many NAFLD patients do you treat in a month?

a) < 10 patients / month

b) 10-20 patients / month

c) 20-40 patients / month

d) 40-60 patients / month

e) > 60 patients / month

2. NAFLD is metabolic condition and commonly associated with Obesity, DM and Dyslipidemia. So, in which type of patients, based on major guidelines such as AASLD/EASL/ADA do you recommend screening of NAFLD disease? (Can tick multiple options)

a) T2DM & Pre-diabetics with elevated ALT

b) Dyslipidemia

c) Hypertension

d) Prior h/o Cardiovascular disease

3. In routine clinical practice; which diagnostic tests do you apply to confirm NAFLD diagnosis in suspected patients? (Can tick multiple options)

a. Liver enzymes

b. Ultrasonography

c. Transient Elastography (Fibroscan)

d. Liver Biopsy

4. What percentage of your Diabetic patients do you screen for Liver Enzyme / Ultrasonography for suspected NAFLD?

a) <20%

b) 20% - 40%

c) 40% -50%

d) >50%

5. Which of below mentioned tests would you prefer to evaluate risk of fibrosis in NAFLD patients? (Can tick multiple options)

a. FIB-4 Index calculator

b. Transient Elastography (Fibroscan)

c. MR Elastography

d. Liver Biopsy

6. In current routine practice, which is most common medication that do you prescribe in NAFLD treatment?

a) Pioglitazone

b) Ursodeoxycholic Acid

c) Saroglitazar

d) Any other:

7. In current time, Saroglitazar is the only approved medication for NAFLD management. So in how many NAFLD patients would you like to start or switch to Saroglitazar treatment ?

a) < 10%

b) 10% - 20%

c) 20% - 40%

d) 40% - 50%

e) > 50%

8. What duration of therapy do you recommend for Saroglitazar to your NAFLD patients?

a) 16 weeks

b) 24 weeks

c) 48 weeks

d) 52 weeks

9. In what % of your NAFLD patients, do you observe absolute fat reduction after Saroglitazar therapy in USG?

a) <20%

b) 20% - 40%

c) 40% - 50%

d) 50% - 60%

e) > 60%

10. How much average Liver enzyme reduction, do you observe in NAFLD patients after Saroglitazar treatment ?

a) <30%

b) 30% - 50%

c) 50% - 70%

d) > 70%

11. In how many NAFLD patients after Saroglitazar treatment, do you find regression in level of fibrosis?

a) <30%

b) 30% - 50%

c) 50% - 70%

d) > 70%

12. How would you like to scale safety experience of Saroglitazar in routine practice?

a) 0 = No any adverse events

b) 1= Very few adverse events

c) 2= Mild adverse events

d) 3= Moderate adverse events

e) 4= Serious adverse events

f) 5= Extremely serious adverse events